Topics

Epizyme sells Royalty Pharma future royalties on Japanese sales of tazemetostat

14:40 EST 7 Nov 2019 | Elsevier Business Intelligence

Epizyme Inc. assigned Royalty Pharma the future royalty streams on Japanese sales of tazemetostat (an oral EZH2 inhibitor can...

Original Article: Epizyme sells Royalty Pharma future royalties on Japanese sales of tazemetostat

NEXT ARTICLE

More From BioPortfolio on "Epizyme sells Royalty Pharma future royalties on Japanese sales of tazemetostat"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...